Literature DB >> 32340027

Procalcitonin in special patient populations: Guidance for antimicrobial therapy.

Susan E Smith1, Justin Muir2, Julie Kalabalik-Hoganson3.   

Abstract

PURPOSE: Procalcitonin (PCT) is an endogenous hormone that increases reliably in response to bacterial infection, and measurement of serum PCT levels is recommended to help guide antimicrobial therapy. The utility of PCT assessment in special patient populations (eg, patients with renal dysfunction, cardiac compromise, or immunocompromised states and those undergoing acute care surgery) is less clear. The evidence for PCT-guided antimicrobial therapy in special populations is reviewed.
SUMMARY: In the presence of bacterial infection, nonneuroendocrine PCT is produced in response to bacterial toxins and inflammatory cytokines, resulting in markedly elevated levels of serum PCT. Cytokine induction in nonbacterial inflammatory processes activated by acute care surgery may alter the interpretation of PCT levels. The reliability of PCT assessment has also been questioned in patients with renal dysfunction, cardiac compromise, or immunosuppression. In many special populations, serum PCT may be elevated at baseline and increase further in the presence of infection; thus, higher thresholds for diagnosing infection or de-escalating therapy should be considered, although the optimal threshold to use in a specific population is unclear. Procalcitonin-guided antimicrobial therapy may be recommended in certain clinical situations.
CONCLUSION: Procalcitonin may be a reliable marker of infection even in special populations with baseline elevations in serum PCT. However, due to unclear threshold values and the limited inclusion of special populations in relevant clinical trials, PCT levels should be considered along with clinical criteria, and antibiotics should never be initiated or withheld based on PCT values alone. Procalcitonin measurement may have a role in guiding de-escalation of antibiotic therapy in special populations; however, the clinician should be aware of disease states and concomitant therapies that may affect interpretation of results. © American Society of Health-System Pharmacists 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  cardiology; immunosuppression; operative; procalcitonin; renal insufficiency; surgical procedures; trauma

Year:  2020        PMID: 32340027     DOI: 10.1093/ajhp/zxaa089

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  2 in total

1.  Drug-induced hypersensitivity syndrome with high procalcitonin levels due to piperacillin/tazobactam and meropenem: A case report.

Authors:  Gao Song; Meng-Qun Cheng; Rong Li; Cai-Qiong Zhang; Ping Sun
Journal:  Front Med (Lausanne)       Date:  2022-10-04

2.  Diagnostic Value of Procalcitonin in Transplant Patients Receiving Immunosuppressant Drugs: A Retrospective Electronic Medical Record-Based Analysis.

Authors:  Hyojin Chae; Nicholas Bevins; Gregory B Seymann; Robert L Fitzgerald
Journal:  Am J Clin Pathol       Date:  2021-11-08       Impact factor: 5.400

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.